AbCellera Biologics Inc. Other Noncash Income (Expense)
AbCellera Biologics Inc. (ABCL) reported Other Noncash Income (Expense) of -$7.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-05
- AbCellera Biologics Inc. other noncash income (expense) for the quarter ending 2026-06-30 was -$4.64M, a 316.61% decline year-over-year.
- AbCellera Biologics Inc. other noncash income (expense) for the quarter ending 2026-03-31 was -$2.38M.
- AbCellera Biologics Inc. other noncash income (expense) for the quarter ending 2025-12-31 was $4.32M.
- AbCellera Biologics Inc. other noncash income (expense) for the quarter ending 2025-09-30 was -$918.00K, a 103.31% decline year-over-year.
- AbCellera Biologics Inc. other noncash income (expense) for fiscal 2025 was $3.33M, a 83.10% decline from fiscal 2024.
- AbCellera Biologics Inc. other noncash income (expense) for fiscal 2024 was $19.71M.
- AbCellera Biologics Inc. other noncash income (expense) for fiscal 2023 was -$2.24M.
- AbCellera Biologics Inc. other noncash income (expense) for fiscal 2022 was -$3.34M.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 3 month as first filed | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 6 month as first filed | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 9 month as first filed | Other Noncash Income (Expense) 12 month | Other Noncash Income (Expense) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$4.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$7.02M 10-Q · filed 2026-08-05 | -$2.70M derived: sum of 3 quarters · filed 2026-08-05 | -$3.62M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$2.38M 10-Q · filed 2026-05-11 | $1.94M derived: sum of 2 quarters · filed 2026-05-11 | $1.02M derived: sum of 3 quarters · filed 2026-05-11 | $3.17M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $4.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.40M derived: sum of 2 quarters · filed 2026-02-24 | $5.54M derived: sum of 3 quarters · filed 2026-08-05 | $3.33M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | -$918.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.23M derived: sum of 2 quarters · filed 2026-08-05 | -$988.00K 10-Q · filed 2025-11-06 | -$17.17M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $2.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$70.00K 10-Q · filed 2026-08-05 | $667.00K 10-Q · filed 2025-08-07 | -$16.25M derived: sum of 3 quarters · filed 2026-08-05 | $11.45M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | -$2.21M 10-Q · filed 2026-05-11 | -$18.39M derived: sum of 2 quarters · filed 2026-05-11 | $9.30M derived: sum of 3 quarters · filed 2026-05-11 | $19.20M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | -$16.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $11.52M derived: sum of 2 quarters · filed 2026-02-24 | $21.41M derived: sum of 3 quarters · filed 2026-02-24 | $19.71M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $27.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $37.59M derived: sum of 2 quarters · filed 2025-11-06 | $35.89M 10-Q · filed 2025-11-06 | $27.30M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $9.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $8.19M 10-Q · filed 2025-08-07 | -$398.00K derived: sum of 3 quarters · filed 2026-02-24 | $1.53M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | -$1.71M 10-Q · filed 2024-05-07 | -$10.30M derived: sum of 2 quarters · filed 2026-02-24 | -$8.37M derived: sum of 3 quarters · filed 2026-02-24 | -$7.58M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | -$8.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$6.67M derived: sum of 2 quarters · filed 2026-02-24 | -$5.87M derived: sum of 3 quarters · filed 2026-02-24 | -$2.24M 10-K · filed 2026-02-24 | -$277.00K 10-K · filed 2024-02-20 | |||
| 2023-09-30 | $1.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $2.72M derived: sum of 2 quarters · filed 2024-08-06 | $6.35M 10-Q · filed 2023-11-02 | $6.32M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $795.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $4.43M 10-Q · filed 2024-08-06 | $4.39M derived: sum of 3 quarters · filed 2025-02-27 | $789.00K derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | $3.63M 10-Q · filed 2024-05-07 | $3.60M derived: sum of 2 quarters · filed 2025-02-27 | -$6.00K derived: sum of 3 quarters · filed 2025-02-27 | -$300.00K derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | -$38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$3.64M derived: sum of 2 quarters · filed 2025-02-27 | -$3.93M derived: sum of 3 quarters · filed 2025-02-27 | -$3.34M 10-K · filed 2025-02-27 | -$8.55M 10-K · filed 2023-02-21 | |||
| 2022-09-30 | -$3.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$3.90M derived: sum of 2 quarters · filed 2023-11-02 | -$3.30M 10-Q · filed 2023-11-02 | -$6.97M derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-06-30 | -$294.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $298.00K 10-Q · filed 2023-08-03 | -$3.37M derived: sum of 3 quarters · filed 2024-02-20 | -$651.00K derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-03-31 | $592.00K 10-Q · filed 2023-05-04 | -$3.07M derived: sum of 2 quarters · filed 2024-02-20 | -$357.00K derived: sum of 3 quarters · filed 2024-02-20 | -$262.00K derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2021-12-31 | -$3.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$949.00K derived: sum of 2 quarters · filed 2024-02-20 | -$854.00K derived: sum of 3 quarters · filed 2024-02-20 | -$1.29M 10-K · filed 2024-02-20 | -$3.57M 10-K · filed 2022-02-25 | |||
| 2021-09-30 | $2.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $2.81M derived: sum of 2 quarters · filed 2022-11-08 | $2.38M 10-Q · filed 2022-11-08 | -$888.00K 10-Q · filed 2021-11-10 | -$1.89M derived: sum of 4 quarters · filed 2023-02-21 | |||
| 2021-06-30 | $95.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$337.00K 10-Q · filed 2022-08-09 | $419.00K 10-Q · filed 2021-08-13 | -$4.60M derived: sum of 3 quarters · filed 2023-02-21 | -$5.29M derived: sum of 4 quarters · filed 2023-02-21 | |||
| 2021-03-31 | -$432.00K 10-Q · filed 2022-05-10 | $191.00K 10-Q · filed 2021-05-14 | -$4.70M derived: sum of 2 quarters · filed 2023-02-21 | -$5.38M derived: sum of 3 quarters · filed 2023-02-21 | -$5.17M derived: sum of 4 quarters · filed 2023-02-21 | |||
| 2020-12-31 | -$4.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | -$4.95M derived: sum of 2 quarters · filed 2023-02-21 | -$4.74M derived: sum of 3 quarters · filed 2023-02-21 | -$4.71M 10-K · filed 2023-02-21 | ||||
| 2020-09-30 | -$685.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$468.00K derived: sum of 2 quarters · filed 2021-11-10 | -$440.00K 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $217.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $245.00K 10-Q · filed 2021-08-13 | ||||||
| 2020-03-31 | $28.00K 10-Q · filed 2021-05-14 | |||||||
| 2019-12-31 | -$194.00K 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |